ArticleEuropean journal of haematology2014
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Article in European journal of haematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders.Hematology reports · 2025Review
- Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.BMC medicine · 2025Article
- Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.American journal of cancer research · 2025Article
- A case report of biclonal immunoglobulin D lambda/lambda multiple myeloma in patient with liver echinococcosis.Biochemia medica · 2024Article
- Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.Blood advances · 2022Article
- Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients.Frontiers in oncology · 2022Article
- Coexistent light chain deposition disease, light chain cast nephropathy, and vascular light chain amyloidosis in a patient with IgD lambda multiple myeloma.International urology and nephrology · 2021Article
- Immunoglobulin D-λ/λ biclonal multiple myeloma: A case report.World journal of clinical cases · 2021Article
- A Rare Case of Extramedullary Multiple Myeloma Presenting as Masses on the Breast and Chest Wall Complicated with Sjogren's Syndrome.International journal of general medicine · 2021Article
- Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.CEN case reports · 2020Article
- Early stage IgD multiple myeloma in a 50-year-old man.Proceedings (Baylor University. Medical Center) · 2020Article
- Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.Cancer communications (London, England) · 2019Article
- Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.Blood advances · 2019Article
- Review
- Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.International journal of molecular sciences · 2018Article
- [Clinical characteristics analyses of 27 cases of immunoglobin D multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- [The significance of serum IgD quantitation for evaluation of clinical efficacy in IgD multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry.Journal of the American Society of Nephrology : JASN · 2015Article
- Aggressive FLC Escape in a Patient with IgD Myeloma.Case reports in hematology · 2015Article
- Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture.Case reports in oncologyArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesImmunoglobulin D (IgD) multiple myeloma is an uncommon variant of the disease probably associated with poorer prognosis. However, data on IgD myeloma patients treated in the novel agent era are lacking.
methodsTo assess the frequency and the specific characteristics and evaluate the outcome of patients with IgD myeloma, we analyzed the database of the Greek Myeloma Study Group.
resultsBetween January 2000 and December 2012, among the 1239 patients with symptomatic myeloma, 31 (2.5%) were diagnosed with IgD myeloma. The median age of patients with IgD myeloma was 65 yr (range 26-80 yr) versus 68 yr (range 23-96 yr) of all others, and 84% had lambda light chain (vs. 38% of the patients with other subtypes). Patients with IgD myeloma presented more often with features of high-risk disease, that is, with advanced ISS, high LDH, significant renal dysfunction, and large amounts of Bence Jones proteinuria. Response to primary therapy was similar to other patients, although there was a trend for better quality of responses in patients with IgD myeloma. The median survival of these patients was 51.5 months versus 50.7 months for patients of other subtypes. In a multivariate model to adjust for differences in prognostic features, IgD myeloma was not associated with a different prognosis.
conclusionThe incidence of IgD myeloma is 2.5%. Although patients with IgD myeloma present more often with high-risk features, their outcome in the era of novel agents is similar to that of patients with other myeloma subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.